The automated and closed cell therapy processing system market is expected to expand at a 22.8% CAGR from 2023 to 2033. This market is estimated to value from US$ 1,199.14 million in 2023 to US$ 9,350.92 million in 2033.
Increasing Integration of Software Technologies and Sophisticated Therapy Development Procedures is also Expected to Drive Market Growth
For controlling and sustaining the cell therapy process, automated and closed cell therapy processing systems are used. The system includes manufacturing software and hardware, which aids in the entire research and development process. The technology is a gift to researchers because it assists them in clinical studies through commercial approval. This can aid in the development and avoidance of manual manufacturing delays. Several scale levels of standardisation can be accomplished for diverse production processes.
Researchers believe automated and closed cell therapy processing systems to be simple to use and dependable, as they aid in converting cell therapy from discovery to commercialization.
The increasing number of investments in the market for automated and closed cell therapy processing systems is the key driver of market expansion in the next years. Furthermore, the growing number of cell therapies provides the market with profitable potential. Cell treatment processing is a critical activity that necessitates extreme precision while treating the cells.
The usage of physical labor has been determined to be inefficient because it increases the risk of the process. Also, manual processing increases the possibility of contamination. As a result, the combination of advanced medicines and automated systems is quickly rising.
The adoption of automated systems has aided in the centralization of cell therapy processes, which has benefited manufacturers in a variety of ways.
| Report Attribute | Details |
|---|---|
| Automated and Closed Cell Therapy Processing System Market Value (2023) | US$ 1199.14 million |
| Automated and Closed Cell Therapy Processing System Market Anticipated Value (2033) | US$ 9350.92 million |
| Automated and Closed Cell Therapy Processing System Market Growth Rate (2023 to 2033) | 22.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The automated and closed cell therapy processing system market accounted for US$ 976.50 million in 2022, expanding at a 22.4% CAGR from 2018 to 2022.
Cell therapy technologies are critical in medicine and the cell therapy sector, which has arisen as a crucial factor in medical practice. Furthermore, various cell treatment approaches share functions such as medication delivery, gene therapy, cancer vaccinations, tissue engineering, and regenerative medicine. The distribution of cell therapy products can range from injections to surgical implantation using specialized equipment.
The increasing popularity of regenerative medicines and cell therapies is one of the important factors driving the market growth. The multiple advantages afforded by automation technologies for the development of these therapies are further driving market expansion. Furthermore, the increasing mix of software technologies and complex therapy development techniques is bolstering the market growth.
| Historical CAGR (2018 to 2022) | 22.4% |
|---|---|
| Forecast CAGR (2023 to 2033) | 22.8% |
As per the FMI analysts, a valuation of US$ 9350.92 million by 2033 end is estimated for the market.
| Year | Market Valuation |
|---|---|
| 2016 | US$ 284.76 million |
| 2021 | US$ 795.20 million |
| 2022 | US$ 976.50 million |
| 2023 | US$ 1199.14 million |
| 2033 | US$ 9350.92 million |
Regenerative medicine is a branch of medicine that involves the replacement of damaged tissues or organs. Regenerative medicine is concerned with replacing and rebuilding tissue or organ damage caused by a specific disease or event.
The growing importance of stem cells in regenerative medicine results in increasing demand for regenerative medicine from the healthcare industry. This factor remains a significant factor driving the creation of automated and closed-cell therapy processing systems.
Cancer and other chronic diseases that require long-term therapy have increased the popularity of regenerative medicine. Stem cell uses are part of regenerative medicine. Stem cells can be divided indefinitely and are employed as a first-line source for regenerative therapy.
Regenerative medicine is a branch of medicine that uses various methods to repair, regrow, or replace diseased or damaged cells, organs, or tissues. Furthermore, regenerative medicine encompasses the synthesis and application of therapeutic stem cells, tissue development, and the creation of artificial organs. Due to their high accuracy and effectiveness, regenerative medicines and cell therapies are expected to see a surge in demand, driving the market growth.
Principal Consultant
Chronic disease refers to a category of diseases that include cardiovascular disease, cancer, and diabetes, among others. The global population is experiencing an increase in the prevalence of chronic diseases. It is primarily linked to sedentary behavior, an unhealthy diet, and cigarette use.
Chronic disease, according to the USA Centers for Disease Control and Prevention (CDC), is a condition that lasts longer than a year. This disease requires prompt medical attention. It limits everyday activities also.
As cell therapies become popular, the market for automated processing systems needs experienced personnel to perform these therapies and operate automated systems. The shortage of skilled specialists, on the other hand, is expected to stymie the expansion of the automated and closed cell therapy processing system market over the forecast period.
The use of technologically advanced and extremely intricate flow cytometers and spectrophotometers to generate a large number of data outputs that require knowledge to comprehend and assess might impede the market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The complete cell therapy manufacturing process is made up of several phases, each of which requires a starting material. The global need for automated and closed-cell therapy processing systems has resulted in a scarcity of raw materials required for good medical practice (GMP).
The market is experiencing a bottleneck in the supply of plasmids and viral vectors, which are proven GMP-based raw materials necessary in the cell therapy process.
The difficulties in procuring starting materials such as bone marrow, blood, and apheresis provide a hindrance to the market's expansion. As a result, the global automated and closed-cell therapy processing system market is constrained by a scarcity of raw materials.
Governments and big pharmaceutical corporations are investing in research and development to accelerate the discovery of new therapies for a variety of health ailments. Increasing research and development investment in cell therapy research might promote market expansion by facilitating the discovery of novel automated and closed-cell therapies.
Increased research and development efforts in the pharmaceutical sector are expected to provide significant income for the market.
The United States of America with a CAGR of 20.7% from 2015 to 2021 is the prominent market for automated and closed cell therapy. The market for automated and closed cell therapy processing systems in the United States of America is expected to cross US$ 2.2 million by the end of 2032 with an absolute dollar opportunity of US$ 1.9 Million.
The market in the United Kingdom is expected to reach a valuation of US$ 312 million by 2032. Growing at a CAGR of 21.2%, the market in the country is projected to cross an absolute dollar opportunity of US$ 155.3 million from 2022 to 2032.
In Japan, the market is projected to register a CAGR of 24.1% during the forecast period. With an absolute dollar opportunity of US$ 262 million from 2022 to 2032, the market in the country is expected to reach US$ 296 million by 2032.
The market in South Korea is expected to reach US$ 193 million by 2032. With a CAGR of 26.1% during the forecast period, the market is expected to register an absolute dollar opportunity of US$ 173 Million.
The separation workflow category is predicted to expand significantly in the automated and closed-cell therapy processing system market. Separation is an important component of the closed-cell therapy processing system.
Separation of cell components is required for doing the research in a timely manner. The cell separation revealed minute data about genetic modification, molecular analysis, hybridoma creation, and so on. As a result, cell separation is critical for future research and development in research and academic contexts.
The market for the Non-Stem Cell Therapy type expanded at a CAGR of 17.2% from 2015 to 2021. The success of CAR-T therapies has shifted investment to non-stem cell therapy development, resulting in increased revenue for the industry.
Companies in the market are hugely collaborating and forming partnerships in order to create new regenerative therapies for the treatment of chronic diseases. Such research efforts are primarily focused on non-stem cell uses, which is fueling the non-stem cell treatment segment's expansion.
The enormous therapeutic potential of cell and tissue-based engineering is predicted to allow the segment to increase at a notable rate during the forecast period.
Some of the recent developments of automated and closed cell therapy processing System Market providers are as follows:
| Attribute | Details |
|---|---|
| Market Size Value In 2023 | US$ 1199.14 million |
| Market Size Value in End of Forecast (2033) | US$ 9350.92 million |
| Market Analysis | US$ million for Value |
| Key Region Covered | North America; Europe; Asia Pacific; Latin America; The Middle East & Africa |
| Key Segments | By Type, By Workflow, By Scale, By Region |
| Key Companies Profiled | Miltenyi Bio tec; Lonza; Fresenius Kabi; Cytiva; Bio Spherix; Terumo; Cellares; Sartorius |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The automated and closed cell therapy processing systems market size will reach US$ 1199.14 million in 2023.
The automated and closed cell therapy processing systems market is set to surge at a robust 22.8% CAGR, reaching a noteworthy valuation of US$ 9350.92 million by 2033.
The automated and closed cell therapy processing systems market demonstrated a 22.4% CAGR from 2018 to 2022, recording a valuation of US$ 976.50 million in 2022
The automated and closed cell therapy processing systems market beckons stakeholders with opportunities in innovative medical technologies.
The non-stem cell therapy type demonstrated significant expansion, registering a robust CAGR of 17.2% between 2015 and 2021.
1. Executive Summary | Automated and Closed Cell Therapy Processing System Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Workflow 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Workflow, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Workflow, 2023 to 2033 5.3.1. Cryopreservation 5.3.2. Fill-finish 5.3.3. Separation 5.3.4. Expansion 5.3.5. Apheresis 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Workflow, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Workflow, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033 6.3.1. Stem Cell Therapy 6.3.2. Non-stem Cell Therapy 6.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Scale 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Scale, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Scale, 2023 to 2033 7.3.1. Commercial Scale 7.3.2. R&D Scale 7.4. Y-o-Y Growth Trend Analysis By Scale, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Scale, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Workflow 9.2.3. By Type 9.2.4. By Scale 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Workflow 9.3.3. By Type 9.3.4. By Scale 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Workflow 10.2.3. By Type 10.2.4. By Scale 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Workflow 10.3.3. By Type 10.3.4. By Scale 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Workflow 11.2.3. By Type 11.2.4. By Scale 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Workflow 11.3.3. By Type 11.3.4. By Scale 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Workflow 12.2.3. By Type 12.2.4. By Scale 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Workflow 12.3.3. By Type 12.3.4. By Scale 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Workflow 13.2.3. By Type 13.2.4. By Scale 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Workflow 13.3.3. By Type 13.3.4. By Scale 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Workflow 14.2.3. By Type 14.2.4. By Scale 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Workflow 14.3.3. By Type 14.3.4. By Scale 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Workflow 15.2.3. By Type 15.2.4. By Scale 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Workflow 15.3.3. By Type 15.3.4. By Scale 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Workflow 16.1.2.2. By Type 16.1.2.3. By Scale 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Workflow 16.2.2.2. By Type 16.2.2.3. By Scale 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Workflow 16.3.2.2. By Type 16.3.2.3. By Scale 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Workflow 16.4.2.2. By Type 16.4.2.3. By Scale 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Workflow 16.5.2.2. By Type 16.5.2.3. By Scale 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Workflow 16.6.2.2. By Type 16.6.2.3. By Scale 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Workflow 16.7.2.2. By Type 16.7.2.3. By Scale 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Workflow 16.8.2.2. By Type 16.8.2.3. By Scale 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Workflow 16.9.2.2. By Type 16.9.2.3. By Scale 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Workflow 16.10.2.2. By Type 16.10.2.3. By Scale 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Workflow 16.11.2.2. By Type 16.11.2.3. By Scale 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Workflow 16.12.2.2. By Type 16.12.2.3. By Scale 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Workflow 16.13.2.2. By Type 16.13.2.3. By Scale 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Workflow 16.14.2.2. By Type 16.14.2.3. By Scale 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Workflow 16.15.2.2. By Type 16.15.2.3. By Scale 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Workflow 16.16.2.2. By Type 16.16.2.3. By Scale 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Workflow 16.17.2.2. By Type 16.17.2.3. By Scale 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Workflow 16.18.2.2. By Type 16.18.2.3. By Scale 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Workflow 16.19.2.2. By Type 16.19.2.3. By Scale 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Workflow 16.20.2.2. By Type 16.20.2.3. By Scale 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Workflow 16.21.2.2. By Type 16.21.2.3. By Scale 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Workflow 17.3.3. By Type 17.3.4. By Scale 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Lonza 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. BioSpherix 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Cellares 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Sortorius 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Cytiva 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. ThermoGenesis Holdings Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Thermo Fisher Scientific Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. MiltenyiBiotec 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Fresenius Kabi 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Pfizer 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Automated and Closed Cell Therapy Processing Systems Market
